Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

All Boosters Now Approved - COVID-19 Update #106

10/22/2021

 
  • In September 2021, the FDA amended the EUA for the Pfizer-BioNTech COVID-19 Vaccine to allow a booster dose, given at least six months after completion of the second dose to patients 65 years and older or who are at high risk for severe COVID-19, which includes healthcare professionals, frontline workers and people that live in group settings. The CDC agreed and also recommended a booster dose for these groups. 
  • On 10/14/2021, the VRBAC voted 19 to 0 to recommend amending the EUA for the Moderna COVID-19 vaccine to include a booster dose of 50 mcg (100 mcg is used for the primary series) given at least 6-months after the primary series is completed in patients 65 or older or those 18 and older at high risk of severe COVID-19. The FDA agreed and amended the EUA for the Moderna COVID-19 Vaccine, on 10/20/2021, to allow a booster dose, given at least six months after completion of the second dose to patients 65 years and older or who are at high risk for severe COVID-19, which includes healthcare professionals, frontline workers and people that live in group settings. The approved booster dose if 50mcg, which is half the strength of the primary series dose.
  • On 10/15/2021, the VRBAC voted 19 to 0 to recommend an amendment to the Johnson & Johnson COVID-19 vaccine EUA allowing a second immunization with the vaccine for all patients 18 and older at least two months after the initial injection. The FDA agreed and amended the EUA for the J&J COVID-19 Vaccine, on 10/20/2021, to allow a booster dose, given at least two months after completion of the second dose for all patients 18 and older at least two months after the initial injection.
  • After discussing the J&J booster, the VRBAC discussed use of a different COVID-19 vaccine than a patient initially received, as a booster dose. A pre-print draft of a 29-day, 458 patient, Phase I/II, NIH-sponsored study found that a booster dose increased antibody titers for all combinations of vaccines received. The largest increase was in patients who had originally received the J&J vaccine and then received a booster dose with either mRNA vaccine. In the study the primary series dose of the Moderna vaccine (100 mcg) was used, while Moderna is requesting use of a 50 mcg dose for a booster. VRBAC was supportive of using an mRNA vaccine after an initial J&J vaccination but did not make a formal recommendation. However, the FDA expanded the EUA for all three approved vaccines on 10/20/2021 to allow any of the vaccines to be used as a heterologous (or “mix and match”) booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.
  • CDC’s ACIP unanimously (15-0) approved booster doses of the Moderna and J&J COVID-19 vaccines, on 10/21/2021, in line with the expanded EUA’s by the FDA. ACIP also endorsed use of any of the three approved vaccines as booster for eligible patients that have completed a primary series. The CDC formerly recommended booster doses for the Moderna and J&J COVID-19 vaccines, on 10/21/2021, as recommended by ACIP and approved by the FDA. CDC also agreed that any of the three approved vaccines can be used as booster for eligible patients that have completed a primary series with the same or one of the other vaccines. Booster doses with Moderna and J&J COVID-19 vaccines became available on 10/22/2021.

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.